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Abstract
Background: Baseline low platelet count (< 150,000/μL) increases the risk of on-treatment severe
thrombocytopenia (platelet count < 50,000/μL) in patients with chronic hepatitis C (CHC) undergoing antiviral
therapy, which may interrupt treatment. The purpose of this study was to identify risk factors for severe
thrombocytopenia during treatment for CHC in patients with baseline thrombocytopenia.
Methods: Medical records were reviewed for 125 patients with CHC treated with antiviral therapy according to the
standard of care, with regular follow-up examinations. Early platelet decline was defined as platelet decrease during
the first 2 weeks of therapy.
Results: Severe thrombocytopenia developed in 12.8% of patients with baseline thrombocytopenia, and predicted
a higher therapeutic dropout rate. Multivariate analysis revealed baseline platelet count < 100,000/μL and rapid
early platelet decline (> 30% decline in the first 2 weeks) were significantly associated with severe
thrombocytopenia (P < 0.001 and 0.003, odds ratios, 179.22 and 45.74, respectively). In these patients, baseline PLT
≥ 100,000/μL and lack of rapid early platelet decline predicted absence of severe thrombocytopenia (negative
predictive values were 95.1% and 96.6%, respectively). In contrast, baseline platelet count < 100,000/μL combined
with rapid early platelet decline predicted severe thrombocytopenia (positive predictive value was 100%).
Conclusions: For patients with CHC on antiviral therapy, baseline platelet counts < 100,000/μL and rapid early
platelet decline can identify patients at high risk of developing on-treatment severe thrombocytopenia.
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Background
Patients with chronic hepatitis C (CHC) treated with
antiviral therapy consisting of pegylated interferon-a
(peg-IFN-a) and ribavirin experience a response super-
ior to that of therapies used in the past. This combina-
tion is the current standard of care [1]; however, side
effects, especially hematologic abnormalities, may
decrease both therapeutic adherence and the therapeutic
success rate. Thrombocytopenia is one of the potential
hematologic abnormalities associated with peg-IFN-a-
based therapy [2-4].
One recent study reported that development of a platelet
count < 50,000/μL was independently associated with
bleeding during antiviral therapy [5]. In clinical practice,
there is no approved therapy for reversing the decline in
platelet count, even though some anti-thrombocytopenia
therapies are currently under investigation [6]. Reduction
o ft h ed o s eo fp e g - I F N - a (either peg-IFN-a-2a or peg-
IFN-a-2b) is recommended for patients suffering from
platelet counts < 50,000/μL, and cessation of anti-viral
treatment is recommended for platelet counts < 25,000/μL
[7]. Discontinuation of anti-viral therapy is the only way to
prevent progressive thrombocytopenia; however, disconti-
nuation of therapy may reduce the rate of viral clearance
and sustained virological response (SVR) [8].
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induced severe thrombocytopenia are essential, but are
rarely conducted. Baseline thrombocytopenia is reportedly
independently and strongly associated with the develop-
ment of a platelet count < 50,000/μL during antiviral ther-
apy [5]. Hence, this study was designed to document more
clearly the changes in platelet counts, and to investigate
risk factors for treatment-induced severe thrombocytopenia
(i.e., platelet count < 50,000/μL) in patients with pretreat-
ment thrombocytopenia, undergoing standard antiviral
therapy for CHC.
Methods
Patients
Medical records were reviewed retrospectively for
chronic hepatitis C virus (HCV)-infected patients who
received peg-IFN-a and ribavirin combination therapy in
Kaohsiung Veterans General Hospital, Taiwan between
September 2003 and October 2010. All patients were ser-
opositive for anti-HCV antibody (Ax SYM HCV 3.0;
Abbott Laboratories, Wiesbaden-Delkenheim, Germany),
and had detectable HCV-RNA (Light Cycler, Roche,
Branchburg, NJ, USA), and alanine aminotransferase
(ALT) levels above the upper limit of normal (ULN).
Exclusion criteria included hepatic decompensation, con-
comitant hepatitis B virus or human immunodeficiency
virus infection, hepatitis other than hepatitis C (e.g., auto-
immune or alcoholic hepatitis), or a contraindication to
treatment with IFN-a or ribavirin. Patients with a pre-
treatment normal platelet count were not included in the
analysis. This study was approved by the Institutional
Review Board (IRB) of the Kaohsiung Veterans General
Hospital (the IRB number was VGHKS12-CT1-03).
Treatment and Follow-up
All patients received combination therapy consisting of
ribavirin and either peg-IFN-a-2a or peg-IFN-a-2b based
on the standard of care protocol at the time of their treat-
ment. For patients with genotype non-1, the duration of
treatment was 24 weeks. For patients with genotype 1, the
duration of treatment was 24 to 48 weeks, based on the
rapid virologic response (RVR) after 4 weeks of treatment.
The choice of peg-IFN-a-2a or peg-IFN-a-2b was not ran-
domized, but was made at the discretion of the treating
physician. Peg-IFN-a-2a was administered subcutaneously
at a dose of 180 μg q 7 days, whereas peg-IFN-a-2b was
administered subcutaneously at a dose of 1.5 μg/kg body
weight q 7 days. Ribavirin was prescribed initially at a total
daily dose of 1,000 mg for patients weighing ≤ 75 kg and
1,200 mg for patients weighing > 75 kg.
Baseline complete blood counts and differential counts,
liver function tests, HCV-RNA, genotypes (by a 5’ non-
coding region- and core-based reverse transcriptase PCR
assay with sequencing [9]), and sonographic results were
obtained. Histologic evaluation (scoring by the META-
VIR system [10]) was available in some patients, in whom
liver biopsy was performed. Splenomegaly was defined as
spleen with a long axis > 12 cm by ultrasound [11].
Cirrhosis was diagnosed by ultrasound (using standard
criteria, including: coarse echotexture, irregular surface,
blunt edge, hypertrophic left lobe, splenomegaly), endo-
scopy (esophageal or gastric varices), or liver biopsy.
Thrombocytopenia was defined as platelet count <
150,000/μL. This was further classified as mild (platelet
count ≥ 100,000/μL), moderate (50,000/μL-100,000/μL),
and severe (< 50,000/μL) thrombocytopenia. Dangerous
thrombocytopenia was defined as a platelet count <
25,000/μL. The rate of platelet decline was defined as the
rate of decrease from baseline. After 24-week follow-up,
a platelet count increasing from baseline moderate
thrombocytopenia to mild, or with resolution from base-
line thrombocytopenia to platelet count ≥ 150,000/μL,
was categorized as improvement. In contrast, a platelet
count decreasing from baseline mild or moderate throm-
bocytopenia to moderate or severe thrombocytopenia
was categorized as deterioration. Stable platelet counts
were categorized as stationary.
Information was obtained regarding adherence to treat-
ment, clinical, neuropsychiatric, and hematologic adverse
effects, and biochemical and virologic response, at 2-
week intervals during the first month, 4-week intervals
during the remaining treatment period, and at weeks 4,
12, and 24 after completion of treatment. During treat-
ment, if significant hematologic side effects occurred (e.g.
absolute neutrophil count [ANC] < 750/mm
3 or platelet
count < 50,000/μL), the dose of peg-IFN-a-2a was
decreased to 135 μg/week and the dose of peg-IFN-a-2b
was decreased to 0.75 μg/kg/wk. For an ANC < 500/mm
3
or a platelet count < 25,000/μL, both peg-IFN-a-2a and
peg-IFN- a-2b were discontinued. The dose of ribavirin
was decreased by 200 mg/day if the hemoglobin (Hgb)
declined to < 10 g/dL, and held if Hgb < 8.5 g/dL. If the
adverse effects resolved or diminished, a return to initial
dosing levels was permitted.
Statistical Analysis
Quantitative parameters were expressed as median and
25
th -7 5
th percentile values or mean ± standard devia-
tion. Categorical variables were compared with a c
2 test
and Fisher exact test. The continuous variables were
examined by Kolmogorov-Smirnov test first for their
normality of distribution, and compared with a Student’s
t-test for data with normal distribution, or with a Mann-
Whitney U-test for data without normal distribution. A
Receiver Operating Characteristic (ROC) analysis was
performed to identify the cut-off value with best accu-
racy, of continuous variables with P < 0.1. For identifica-
tion of factors related to severe thrombocytopenia during
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lysis was applied. All statistical analyses were based on
two-side hypothesis tests with a significance level of P <
0.05. All data analyses were performed using SPSS for
Windows (version 12; SPSS Inc., Chicago, IL, USA).
Results
In total, 125 patients with CHC and baseline thrombocy-
topenia who received antiviral therapy with peg-IFN-a
and ribavirin were included in this study (Table 1). The
prevalence of cirrhosis in patients with baseline thrombo-
cytopenia was 22.4% (n = 28), and that of splenomegaly
was 21.6% (n = 27). The changes in platelet counts are
shown in Figure 1, divided into patients with pretreatment
platelet counts between 100,000/μL and 150,000/μL
(Figure 1A), and those with platelet count < 100,000/μL
(Figure 1B). During antiviral therapy, platelet counts
decreased rapidly at the end of the second week in both
subgroups. Overall, 38 (30.4%), 25 (20%), 25 (20%), and
37 (29.6%) patients had a decline in platelet count of ≤
10%, 10%-20%, 20%-30%, and > 30%, respectively. The
lowest platelet counts were documented at a median time
of 12 weeks after initiation of therapy. Platelet counts
recovered after discontinuation of therapy.
After 24-week follow-up of platelet counts, 46 patients
(40.4%) were classified as having improved platelet
counts, and 54 patients (47.4%) stationary platelet counts.
Only 14 patients (12.3%) had a decline in platelet count.
The maximal decline in platelet count was 32% ± 22%
(mean ± standard deviation). A total of 16 patients
(12.8%) had severe thrombocytopenia necessitating dose
reductions, while 32 patients (25.6%) had mild thrombo-
cytopenia, and 77 patients (61.6%) had moderate throm-
bocytopenia. No mortality or morbidity necessitating
hospitalization owing to severe thrombocytopenia was
encountered in the 16 patients. Five patients (4%) discon-
tinued treatment due to thrombocytopenia. These
patients had lower albumin levels (3.8 ± 0.2 mg/dL vs.
4.2 ± 0.3 mg/dL, P = 0.014), lower baseline platelet
counts (94,400 ± 29,399/μL vs. 122,867 ± 19,843/μL, P =
0.035), and higher international normalized ratio (INR)
of prothrombin time (PT) (1.14 ± 0.06 vs. 1.05 ± 0.07,
P = 0.008) than did the other 120 patients, who did not
discontinue treatment because of severe thrombocytope-
nia. These five patients also had higher bilirubin (1.1 ±
0.3 mg/dL vs. 0.8 ± 0.3 mg/dL, P = 0.066) and alkaline
phosphatase levels (129 ± 50 U/L vs. 97 ± 31 U/L, P =
0.099), and a greater proportion of them had splenome-
galy (60% vs. 20.2%, P = 0.068), a difference of borderline
significance. There was a trend of toward discontinuing
therapy due to severe thrombocytopenia in patients with
cirrhosis (40% vs. 21.7% in patients without cirrhosis %,
Table 1 Characteristics of 125 patients with chronic hepatitis C
Variables Median (25
th-75
thpercentile values) or number (percentage)
Age (years) 57 (25-64)
Gender (male/female) 65/60 (52/48)
BMI (kg/m
2) 24.8 (23.0-27.0)
Albumin (g/dL) 4.1 (3.9-4.4)
Total bilirubin (mg/dL) 0.7 (0.6-1.0)
AST (U/L) 107 (72-159)
ALT (U/L) 160 (109-259)
ALK-p (U/L) 96 (72-121)
PT INR 1.04 (1.01-1.08)
WBC (/mm
3) 5,120 (4,403-6,083)
Hgb (g/dL) 14.4 (13.3-15.5)
Platelets (/μL) 125,000 (110,000-140,500)
Fibrosis (F1/2/3/4) 2/31/39/19 (1.6/24.8/31.2/15.2)
#
Necroinflammatory activity (A0/1/2/3) 13/49/21/3 (10.4/38.2/16.8/2.4)
#
Cirrhosis status (yes/no) 28/97 (22.4/77.6)
HCV-RNA (log10, IU/mL) 6.12 (5.39-6.66)
HCV genotype (1/2) 71/54 (56.8/43.2)
Splenomegaly (yes/no) 27/97 (21.6/77.6)
§
Peg-IFN-a-2a/-a-2b 48/77 (38.4/61.6)
Dose of ribavirin (mg/day) 867 (800-1000)
Abbreivations: ALK-p: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; Hgb: hemoglobin; HCV:
hepatitic C virus; PT INR: international normalized ratio of prothrombin time; WBC: white blood cells; Peg-IFN: pegylated-interferon.
#Only the patients undergoing liver biopsy were analyzed for fibrosis and necroinflammatory activity of liver tissue. F1-F4 represent fibrotic scores, and A0-A3
mean necroinflammatory scores, according to METAVIR scoring system [10].
§One patient had undergone splenectomy due to traumatic splenic rupture.
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Figure 1 Sequential changes in platelet counts during treatment with peginterferon-a and ribavirin in patients with pretreatment
platelet counts between 100,000/μL and 150,000/μL (1A), and < 100,000/μL (1B). Each vertical line represents the range of platelet counts.
Each shaded area represents the 25
th -7 5
th percentiles, and each short horizontal line represents the median. F4, F12, and F24 mean follow-up
weeks 4, weeks 12, and weeks 24, respectively. *: Number of the patients was 3. #: Number of the patients was 1.
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cal significance. Nevertheless, the rates of SVR were com-
parable between patients with and without severe
thrombocytopenia (60.0% vs. 68.7%, P = 0.728) during
antiviral therapy.
Low body mass index (P = 0.022), low albumin (P =
0.020), low baseline HCV-RNA level (P = 0.033), geno-
type 2 (P = 0.033), low baseline platelet count (P <
0.001), and high rate of platelet decline at week 2 (i.e.,
early platelet decline, P < 0.001) were significantly corre-
lated with the development of severe thrombocytopenia
by univariate analysis (Table 2). In addition, higher alka-
line phosphatase level (P = 0.065) and lower mean riba-
virin dose (P = 0.079) were borderline significant. The
cut-off values with best accuracy of continuous variables
among these factors were identified by ROC analysis.
The cut-off value of baseline platelet count was 98,500/
μL, while that of early platelet decline was 30.51%. A
baseline platelet count of 100,000/μL, and early platelet
decline of 30%, were used for simplicity. Multivariate
logistic regression (Table 3) revealed that only baseline
platelet count < 100,000/μL( P < 0.001, odds ratio [OR]
179.219; 95% C.I., 12.219-2628.602), and early platelet
decline > 30% (i.e., rapid early platelet decline, P =
0.003, OR, 45.742; 95% C.I., 3.524-593.689) were signifi-
cantly associated with development of severe thrombo-
cytopenia. The positive and negative predict values (i.e.
PPV and NPV) of baseline platelet count < 100,000/μL
were 50% and 95.1%, and those of rapid early platelet
decline were 35.1% and 96.6%, respectively. The PPV
and NPV of a combination of these two factors were
100% and 97.4%, respectively. In the subgroup of
patients with baseline moderate thrombocytopenia,
rapid early platelet decline has not only high PPV
(100%), but also high NPV (91.7%).
Discussion
Thrombocytopenia, encountered frequently among
patients with HCV-related chronic hepatitis and cirrho-
sis, is usually aggravated during IFN-based antiviral
therapy. In several large-scale clinical trials, the inci-
dence of severe on-treatment thrombocytopenia was 3-
5% among all patients with chronic hepatitis C [2-4]. In
the current study, severe thrombocytopenia occurred
more frequently (12.8%) in patients with baseline throm-
bocytopenia. Roomer et al. (2010) documented that
patients with baseline thrombocytopenia were vulnerable
to severe thrombocytopenia [5]. This group also found
Table 2 Significant factors related to severe thrombocytopenia by univariate analysis
Univariate analysis
Factors Platelets < 50 × 10
3/μL Platelets ≥ 50 × 10
3/μL P value
Age, years 58 ± 11 57 ± 10 0.663
Male/female 9/7 56/53 0.463
BMI, kg/m
2 23.37 ± 2.65 25.30 ± 3.19 0.022
ALB, g/dL 3.96 ± 0.30 4.16 ± 0.30 0.020
Total bilirubin, mg/dL 0.9 ± 0.4 0.8 ± 0.3 0.179
AST, U/L 147.44 ± 80.26 116.78 ± 62.33 0.145
ALT, U/L 200 ± 130 196 ± 116 0.909
ALK-p, U/L 113.20 ± 32.52 96.56 ± 31.62 0.065
Prothrombin time (INR) 1.07 ± 0.07 1.05 ± 0.05 0.111
WBC count,/cumm 4954 ± 1169 5303 ± 1215 0.338
Hgb, g/dL 13.86 ± 0.86 14.47 ± 1.49 0.101
Platelets, × 10
3/μL 100.63 ± 23.21 124.83 ± 18.74 < 0.001
Necroinflammatory activity, A0+A1/A2+A3 6/5 56/19 0.152
Fibrosis status, F1+F2/F3+F4 4/8 29/50 0.547
Cirrhosis, yes/no 5/11 23/86 0.269
Splenomegaly yes/no (%) 5/11 22/86 0.247
HCV-RNA, log10 IU/mL 5.41 ± 1.42 6.09 ± 0.96 0.033
HCV genotype- 1/2 5/11 66/43 0.033
Peg-IFN-a-2a/-a-2b 6/10 42/67 0.583
Peg-IFN-a-2a dose, μg/week 180 ± 0 (n = 6) 179 ± 9 (n = 42) 0.705
Peg-IFN-a-2b dose, μg/week 89 ± 11 (n = 10) 93 ± 12 (n = 67) 0.370
Ribavirin dose, mg/day 811 ± 169 900 ± 166 0.079
Rate of PLT decline at week 2, % 38.46 ± 11.53 14.06 ± 21.85 < 0.001
Abbreviations: ALB: albumin; ALK-p: alkaline phosphatase; AST: aspartate aminotransferase; BMI: body mass index; Hgb: hemoglobin; HCV: hepatitic C virus; Peg-
IFN: peginterferon; PLT: platelet
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ciated with bleeding events. In the present study, severe
thrombocytopenia did occur in some patients during
antiviral therapy, but it was not followed by mortality or
major morbidity. Instead, severe thrombocytopenia was
associated with higher rates of premature discontinua-
tion of therapy.
Thrombocytopenia is one of the extrahepatic manifes-
tations of HCV infection. Several mechanisms have been
proposed to account for thrombocytopenia in patients
with CHC [12-15]. Hypersplenism in the cirrhosis stage,
autoantibodies or immune complexes directed against
platelets, direct infection of platelets and megakaryocytes
by HCV, decreased level or activity of thrombopoietin
(TPO), and virus-induced bone marrow suppression or
direct platelet suppression are linked to the low platelet
counts in HCV-infected patients before antiviral therapy
[12-27]. In the present study, 22% of patients with base-
line thrombocytopenia had splenomegaly. In these
patients, hypersplenism might account for thrombocyto-
penia; however, the other 78% of patients with baseline
thrombocytopenia did not have splenomegaly; other
causes such as decreased level or activity of TPO, auto-
immune reaction to platelets, and direct infection of pla-
telets and megakaryocytes by HCV might contribute to
the thrombocytopenia.
The proposed mechanisms of treatment-related throm-
bocytopenia include inhibition of proliferation of mega-
karyocytes from IFN-a [ 2 8 ] ;a n d ,l e s sc o m m o n l y ,
autoimmune reactions [29] and impaired TPO produc-
tion [30]. Direct repression of megakaryopoiesis by IFN-
a by inhibiting TPO-induced signaling was demonstrated
in one in vitro study [31]. In contrast, ribavirin also plays
ar o l ei nt h r o m b o c y t o p e n i ab e c a u s er i b a v i r i ni sa s s o -
ciated with reactive thrombocytosis [3]. Determinants of
severity of thrombocytopenia during antiviral therapy
may be numerous, and the interaction between these fac-
tors may be complicated. Detection of some factors, such
as TPO and anti-platelet antibodies, is rarely conducted
clinically, and is not practical. Hence, the authors of the
current study hypothesized that early platelet dynamics,
which could represent the summation of a variety of fac-
tors, was a relevant factor. Among the limited reports,
the search for predisposing factors for severe thrombocy-
topenia during antiviral therapy disclosed discrepancies
between these studies. For example, Roomer et al. (2010)
found baseline thrombocytopenia and cirrhosis [5],
whereas Nachnani et al. (2010) reported that lower white
blood cell counts, higher alkaline phosphatase, and
higher iron level, were associated with severe thrombocy-
topenia during antiviral therapy [32]. The present study
was aimed at finding factors associated with severe
thrombocytopenia in patients with baseline thrombocyto-
p e n i a ,a n do b s e r v e dt h a tb a s e l i n ep l a t e l e tc o u n t s<
100,000/μL and rapid early platelet decline (> 30%
decline of platelets 2 weeks after initiation of therapy)
were strong factors for predicting the development of
severe thrombocytopenia during antiviral therapy. Lower
baseline platelet counts, which reportedly correlate with
decreased liver function and lower TPO level [17],
account for lower on-treatment platelet counts. Alterna-
tively, rapid early platelet decline may represent higher
repression of megakaryopoiesis, or increased platelet con-
sumption. Further studies assessing megakaryocytes,
autoimmune anti-platelet antibodies, and virological
response during combination therapy are warranted to
elucidate factors associated with rapid early platelet
decline, and consequent development of severe
thrombocytopenia.
The other factor, cirrhosis, reported by Roomer et al.
(2010) as a significant factor in severe thrombocytopenia
during antiviral therapy in the general population with
chronic hepatitis C, was not relevant in the current study.
Although low pretreatment platelet count and albumin
level, suggestive of cirrhosis status, were significant on uni-
variate analysis, the significance of cirrhosis in prediction
of on-treatment severe thrombocytopenia may be
restricted by small sample size. In addition, the majority of
patients without cirrhosis in the present study were classi-
fied as having advanced hepatic fibrosis (F3). It is
Table 3 Multivariate analysis of factors related to severe thrombocytopenia
Multivariate Analysis
Factors P value Odds Ratio 95% Confidence Interval
BMI (< 24.5/≥ 24.5 Kg/m
2) 0.280
ALB (≤ 4.1/> 4.1 g/dL) 0.412
ALK-p (≥ 97/< 97 U/L) 0.646
PLT (< 100,000/≥ 100,000/μL) < 0.001 179.219 12.219-2628.602
HCV-RNA (log10, IU/mL) (≥ 5.95/< 5.95) 0.196
HCV genotype (1/2) 0.419
Ribavirin dose (≤ 24.58/> 24.58) 0.201
Rate of PLT decline at week 2 (early PLT decline, > 30%/≤ 30%) 0.003 45.742 3.524-593.689
Abbreviations: ALB: albumin; ALK-p: alkaline phosphatase; AST: aspartate aminotransferase; PLT: platelet; BMI: body mass index; C.I.: confidence interval; HCV:
hepatitic C virus.
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thrombocytopenia in these patients may also decrease the
difference in the rate of severe thrombocytopenia in
patients with cirrhosis compared with the rate in those
without cirrhosis.
In patients with pretreatment thrombocytopenia, it is
possible to select a group at low risk for severe on-treat-
ment thrombocytopenia by means of baseline platelet
count before antiviral therapy. For pretreatment platelet
count ≥ 100,000/μL, the NPV for severe on-treatment
thrombocytopenia was 95.1%, i.e., the on-treatment inci-
dence of severe thrombocytopenia in the patients with
baseline platelet count ≥ 100,000/μL was only 4.9%, which
is comparable to that of the general population with
chronic hepatitis C during antiviral therapy (which was
reportedly 3-5%). In high-risk patients, it is still possible to
identify those with a relatively low-risk (8.3%) of severe
thrombocytopenia by lack of rapid early platelet decline
(11 among 12 (91.7%) patients with baseline moderate
thrombocytopenia and platelet decline ≤ 30%).
In contrast, patients with platelet count < 100,000/μL
before treatment and a rapid early platelet decline during
antiviral therapy were at very high risk (100%) for severe
thrombocytopenia (positive predictive value was 100%). For
this group of patients, modification of antiviral therapy,
close monitoring, and salvage therapy for thrombocytope-
nia were needed. A TPO-mimetic agent may be beneficial
in these high-risk patients. An emerging TPO-mimetic
agent, eltrombopag, reportedly increases the proportion of
baseline-thrombocytopenic, HCV-infected patients com-
pleting the initial 12 weeks of antiviral therapy, from 36% to
65% (compared with 6% in the control group) in a phase II
study [6]. Eltrombopag is not yet licensed for treatment of
thrombocytopenia in patients with chronic liver disease
because the risk of portal venous thrombosis (PVT)
increased substantially when this drug was administered at
75 mg daily for 14 days [33]. Subsequent PVT had never
been reported in patients undergoing combination therapy
with peg-IFN-a and ribavirin, except in those having
undergone splenectomy or partial splenic embolization
prior to treatment [34,35]. Hence, eltrombopag was
believed to be responsible for PVT, and such conditions
were different from those assessed in the current study.
Nevertheless, cautious use of this drug at a low dose was
recommended in concert with close monitoring of patients
[33]. Still under investigation is the use of other TPO-
mimetic agents, including romiplostim (which has been
approved for treatment of immunological thrombocytope-
nic purpura) in patients with chronic liver disease and
thrombocytopenia,.
The study presented here has several limitations. First,
the choice between peg-IFN-a-2a and peg-IFN-a-2b was
not randomized; however, this study demonstrated that
the choice of peg-IFN-a-2a or peg-IFN-a-2b was not an
independent factor related to severe thrombocytopenia.
A meta-analysis study conducted by Alavian SM et al.
also failed to find significantly different rates of thrombo-
cytopenia (platelet count < 50,000/μL) between both
types of peg-IFN-a (odds ratio 1.37, 95% CI 0.73-2.58)
[36]. Second, the number of patients with baseline
thrombocytopenia was relatively small; therefore, factors
not demonstrated to be significant in this study may
become significant in larger studies. Third, due to the
retrospective nature of our study, further prospective
investigations are needed.
Conclusions
Severe thrombocytopenia (platelet counts < 50,000/μL),
encountered by a substantial portion (12.8%) of patients
with baseline thrombocytopenia, was associated with a
higher rate of premature cessation of therapy. In these
thrombocytopenic patients, pretreatment platelet levels <
100,000/μL and rapid early platelet decline (> 30%
decline of platelets after 2 weeks of therapy) were
strongly associated with the occurrence of treatment-
related severe thrombocytopenia. Patients with pretreat-
ment thrombocytopenia should be informed early about
the potential for development of severe thrombocytope-
nia, should be monitored closely during therapy, and,
potentially, should be administered TPO-mimetic agents.
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